Vanda Pharmaceuticals (VNDA) Operating Expenses (2010 - 2026)

Vanda Pharmaceuticals has disclosed Operating Expenses across 17 years of filings, most recently posting $101.9 million for Q1 2026.

• Operating Expenses for Q1 2026 came in at $101.9 million, up 11.94% year-over-year; the trailing twelve-month figure through Mar 2026 was $378.1 million (up 38.11% YoY), and the FY2025 annual result was $367.3 million, up 53.39% from the prior year.
• Operating Expenses came in at $101.9 million for Q1 2026 at Vanda Pharmaceuticals, up from $97.6 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $101.9 million in Q1 2026 to a low of $44.8 million in Q3 2023.
• The 5-year median for Operating Expenses is $60.9 million (2022), against an average of $68.4 million.
• Across the five-year window, Operating Expenses fell 27.03% in 2023 and jumped 60.62% in 2025, its largest moves.
• Vanda Pharmaceuticals' Operating Expenses stood at $57.9 million in 2022, then decreased by 9.49% to $52.4 million in 2023, then climbed by 21.2% to $63.5 million in 2024, then surged by 53.74% to $97.6 million in 2025, then advanced by 4.48% to $101.9 million in 2026.
• The last three Operating Expenses figures came in at $101.9 million (Q1 2026), $97.6 million (Q4 2025), and $87.5 million (Q3 2025), per Business Quant data.